Impact of switching from bisphosphonates to denosumab, teriparatide, or romosozumab in patients with postmenopausal osteoporosis: a case–control study

Yukishima, Toshitaka; Ebina, Kosuke; Etani, Yuki; Noguchi, Takaaki; Ohmura, Shin-ichiro; Nakata, Ken; Okada, Seiji; Kobayakawa, Tomonori

doi:https://doi.org/10.1007/s00198-025-07386-4

Impact of switching from bisphosphonates to denosumab, teriparatide, or romosozumab in patients with postmenopausal osteoporosis: a case–control study

Yukishima, Toshitaka; Ebina, Kosuke; Etani, Yuki et al.

Osteoporosis International, 2025

アクセス数:1,043件（2025-07-17 14:11 集計）

固定URL: https://hdl.handle.net/11094/100329

閲覧可能ファイル

ファイル	フォーマット	利用条件	サイズ	閲覧回数	利用開始日	説明	information
OsteoporosInt_s00198-025-07386-4	pdf	なし	795 KB	40	2025.02.14

Creative Commons : 表示 - 非営利

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

タイトル	Impact of switching from bisphosphonates to denosumab, teriparatide, or romosozumab in patients with postmenopausal osteoporosis: a case–control study
著者	著者名 Yukishima, Toshitaka
	NRID 1000070612076 1000070612076 ORCID 0000-0002-2426-1024 0000-0002-2426-1024 researchmap permalink k-ebina k-ebina Scopus Author ID 8415453300 8415453300 著者名 Ebina, Kosuke
	NRID 1000060898930 1000060898930 ORCID 0000-0001-5741-5969 0000-0001-5741-5969 researchmap permalink Yetani0302 Yetani0302 著者名 Etani, Yuki
	NRID 1000050812294 1000050812294 researchmap permalink takaakinoguchi takaakinoguchi ORCID 0000-0001-9938-6780 0000-0001-9938-6780 著者名 Noguchi, Takaaki
	著者名 Ohmura, Shin-ichiro
	NRID 1000000283747 1000000283747 researchmap permalink ken-nakata ken-nakata Scopus Author ID 7402151308 7402151308 著者名 Nakata, Ken
	NRID 1000030448435 1000030448435 ORCID 0000-0002-5107-8209 0000-0002-5107-8209 researchmap permalink okadaseiji okadaseiji Scopus Author ID 35079139100 35079139100 著者名 Okada, Seiji
	著者名 Kobayakawa, Tomonori
キーワード等	Bone mineral density
	Bisphosphonates
	Denosumab
	Teriparatide
	Romosozumab
内容	The version of record of this article, first published in Osteoporosis International, is available online at Publisher’s website: https://doi.org/10.1007/s00198-025-07386-4.
抄録	Summary: This case-control study investigated the impact of switching from bisphosphonates to denosumab, teriparatide, or romosozumab in postmenopausal osteoporosis. Romosozumab demonstrated the most significant improvements in bone mineral density, particularly in the lumbar spine and total hip, by reducing bone resorption and increasing bone formation markers. Purpose: To investigate the impact of switching from bisphosphonates (BP) to denosumab (DMAb), teriparatide (TPTD), or romosozumab (ROMO) in postmenopausal osteoporosis. Methods: This retrospective, case-controlled, multicenter study included 389 patients who switched from BP to DMAb, TPTD, or ROMO due to treatment inefficacy. Propensity score matching was used to align patient backgrounds, resulting in 45 patients per group. Baseline characteristics included a mean age of 73.8 years, prior BP treatment duration of 37.1 months, and bone mineral density (BMD) T-scores of -2.8 in the lumbar spine (LS), -2.5 in the total hip (TH), and -2.7 in femoral neck (FN). BMD and bone turnover markers were assessed over 12 months. Results: Following the switch from BP, the ROMO group demonstrated a dual effect of decreased bone resorption and increased bone formation markers. The TPTD group exhibited the highest increases in both markers, while the DMAb group suppressed both. After 12 months, the ROMO group demonstrated significantly greater BMD increases in the LS (11.4%) compared to the DMAb (6.3%; p < 0.001) and TPTD (5.9%; p < 0.001) groups. Additionally, the ROMO group showed greater increases in the TH (3.3%) than TPTD group (0.8%; p < 0.01). Only the ROMO group showed a significant BMD increase in the FN (2.0%; p < 0.01 from baseline). Conclusion: Significant BMD increases were observed in the LS for all groups, in the TH for the ROMO and DMAb groups, and in the FN for the ROMO group. ROMO showed the most substantial BMD improvements following BP therapy.
出版者	Springer Science and Business Media LLC
収録物名	Osteoporosis International
刊行年月	2025-01-16
言語	英語
ハンドルURL	https://hdl.handle.net/11094/100329
PISSN	0937941X
eISSN	14332965
関連情報 (isIdenticalTo)	DOI (出版社版) https://doi.org/10.1007/s00198-025-07386-4
アクセス権	open access
権利情報	This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
出版タイプ	Version of Record
カテゴリ	学術雑誌論文 Journal Article

資源タイプ	学術雑誌論文
ローカル資源タイプ	学術雑誌論文
DCTERMS.bibliographicCitation	Osteoporosis International. 2025
DC.title	Impact of switching from bisphosphonates to denosumab, teriparatide, or romosozumab in patients with postmenopausal osteoporosis: a case–control study
DC.creator	Yukishima, Toshitaka
	Ebina, Kosuke
	Etani, Yuki
	Noguchi, Takaaki
	Ohmura, Shin-ichiro
	Nakata, Ken
	Okada, Seiji
	Kobayakawa, Tomonori
DC.publisher	Springer Science and Business Media LLC
DC.language' scheme='DCTERMS.RFC1766	英語
DCTERMS.issued' scheme='DCTERMS.W3CDTF	2025-01-16
DC.identifier	https://doi.org/10.1007/s00198-025-07386-4
DC.subject	Bone mineral density
	Bisphosphonates
	Denosumab
	Teriparatide
	Romosozumab
DC.description	The version of record of this article, first published in Osteoporosis International, is available online at Publisher’s website: https://doi.org/10.1007/s00198-025-07386-4.
DCTERMS.abstract	Summary: This case-control study investigated the impact of switching from bisphosphonates to denosumab, teriparatide, or romosozumab in postmenopausal osteoporosis. Romosozumab demonstrated the most significant improvements in bone mineral density, particularly in the lumbar spine and total hip, by reducing bone resorption and increasing bone formation markers. Purpose: To investigate the impact of switching from bisphosphonates (BP) to denosumab (DMAb), teriparatide (TPTD), or romosozumab (ROMO) in postmenopausal osteoporosis. Methods: This retrospective, case-controlled, multicenter study included 389 patients who switched from BP to DMAb, TPTD, or ROMO due to treatment inefficacy. Propensity score matching was used to align patient backgrounds, resulting in 45 patients per group. Baseline characteristics included a mean age of 73.8 years, prior BP treatment duration of 37.1 months, and bone mineral density (BMD) T-scores of -2.8 in the lumbar spine (LS), -2.5 in the total hip (TH), and -2.7 in femoral neck (FN). BMD and bone turnover markers were assessed over 12 months. Results: Following the switch from BP, the ROMO group demonstrated a dual effect of decreased bone resorption and increased bone formation markers. The TPTD group exhibited the highest increases in both markers, while the DMAb group suppressed both. After 12 months, the ROMO group demonstrated significantly greater BMD increases in the LS (11.4%) compared to the DMAb (6.3%; p < 0.001) and TPTD (5.9%; p < 0.001) groups. Additionally, the ROMO group showed greater increases in the TH (3.3%) than TPTD group (0.8%; p < 0.01). Only the ROMO group showed a significant BMD increase in the FN (2.0%; p < 0.01 from baseline). Conclusion: Significant BMD increases were observed in the LS for all groups, in the TH for the ROMO and DMAb groups, and in the FN for the ROMO group. ROMO showed the most substantial BMD improvements following BP therapy.
DC.rights	This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
DC.format	100329
citation_title	Impact of switching from bisphosphonates to denosumab, teriparatide, or romosozumab in patients with postmenopausal osteoporosis: a case–control study
citation_author	Yukishima, Toshitaka
	Ebina, Kosuke
	Etani, Yuki
	Noguchi, Takaaki
	Ohmura, Shin-ichiro
	Nakata, Ken
	Okada, Seiji
	Kobayakawa, Tomonori
citation_publisher	Springer Science and Business Media LLC
citation_language	英語
citation_date	2025-01-16
citation_journal_title	Osteoporosis International
citation_doi	https://doi.org/10.1007/s00198-025-07386-4
citation_public_url	https://hdl.handle.net/11094/100329

Impact of switching from bisphosphonates to denosumab, teriparatide, or romosozumab in patients with postmenopausal osteoporosis: a case–control study

閲覧可能ファイル

論文情報

論文詳細を表示